<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31013615</article-id>
<article-id pub-id-type="pmc">6515458</article-id>
<article-id pub-id-type="doi">10.3390/ijms20081962</article-id>
<article-id pub-id-type="publisher-id">ijms-20-01962</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Pathway to Cancer Cachexia: MicroRNA-Regulated Networks in Muscle Wasting Based on Integrative Meta-Analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0649-8279</contrib-id>
<name>
<surname>Freire</surname>
<given-names>Paula Paccielli</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernandez</surname>
<given-names>Geysson Javier</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4803-0933</contrib-id>
<name>
<surname>Cury</surname>
<given-names>Sarah Santiloni</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Moraes</surname>
<given-names>Diogo</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oliveira</surname>
<given-names>Jakeline Santos</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Oliveira</surname>
<given-names>Grasieli</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dal-Pai-Silva</surname>
<given-names>Maeli</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3775-3797</contrib-id>
<name>
<surname>dos Reis</surname>
<given-names>Patrícia Pintor</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-01962">2</xref>
<xref ref-type="aff" rid="af3-ijms-20-01962">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4901-7714</contrib-id>
<name>
<surname>Carvalho</surname>
<given-names>Robson Francisco</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-01962">1</xref>
<xref ref-type="corresp" rid="c1-ijms-20-01962">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-01962"><label>1</label>Department of Morphology, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, São Paulo 18.618-619, Brazil; <email>paula.freire@unesp.br</email> (P.P.F.); <email>jasonfergar@hotmail.com</email> (G.J.F.); <email>sarahscury@gmail.com</email> (S.S.C.); <email>demoraesdiogo2017@gmail.com</email> (D.d.M.); <email>jakoliveira.jo@gmail.com</email> (J.S.O.); <email>oliveira.grase@gmail.com</email> (G.d.O.); <email>maeli.dal-pai@unesp.br</email> (M.-D.-P.-S.)</aff>
<aff id="af2-ijms-20-01962"><label>2</label>Department of Surgery and Orthopedics, Faculty of Medicine, São Paulo State University (UNESP), Botucatu, São Paulo 18.618-687, Brazil; <email>patricia.reis@unesp.br</email></aff>
<aff id="af3-ijms-20-01962"><label>3</label>Experimental Research Unity, Faculty of Medicine, São Paulo State University (UNESP), Botucatu, São Paulo 18.618-687, Brazil</aff>
<author-notes>
<corresp id="c1-ijms-20-01962"><label>*</label>Correspondence: <email>robson.carvalho@unesp.br</email>; Tel.: +55-14-3880-0473</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>8</issue>
<elocation-id>1962</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Cancer cachexia is a multifactorial syndrome that leads to significant weight loss. Cachexia affects 50%–80% of cancer patients, depending on the tumor type, and is associated with 20%–40% of cancer patient deaths. Besides the efforts to identify molecular mechanisms of skeletal muscle atrophy—a key feature in cancer cachexia—no effective therapy for the syndrome is currently available. MicroRNAs are regulators of gene expression, with therapeutic potential in several muscle wasting disorders. We performed a meta-analysis of previously published gene expression data to reveal new potential microRNA–mRNA networks associated with muscle atrophy in cancer cachexia. We retrieved 52 differentially expressed genes in nine studies of muscle tissue from patients and rodent models of cancer cachexia. Next, we predicted microRNAs targeting these differentially expressed genes. We also include global microRNA expression data surveyed in atrophying skeletal muscles from previous studies as background information. We identified deregulated genes involved in the regulation of apoptosis, muscle hypertrophy, catabolism, and acute phase response. We further predicted new microRNA–mRNA interactions, such as miR-27a/<italic>Foxo1</italic>, miR-27a/<italic>Mef2c</italic>, miR-27b/<italic>Cxcl12</italic>, miR-27b/<italic>Mef2c</italic>, miR-140/<italic>Cxcl12</italic>, miR-199a/<italic>Cav1</italic>, and miR-199a/<italic>Junb</italic>, which may contribute to muscle wasting in cancer cachexia. Finally, we found drugs targeting <italic>MSTN</italic>, <italic>CXCL12</italic>, and <italic>CAMK2B</italic>, which may be considered for the development of novel therapeutic strategies for cancer cachexia. Our study has broadened the knowledge of microRNA-regulated networks that are likely associated with muscle atrophy in cancer cachexia, pointing to their involvement as potential targets for novel therapeutic strategies. </p>
</abstract>
<kwd-group>
<kwd>cancer cachexia</kwd>
<kwd>microRNAs</kwd>
<kwd>transcriptome</kwd>
<kwd>protein-protein interaction networks</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-01962" sec-type="intro">
<title>1. Introduction</title>
<p>Cachexia is a syndrome associated with pathological conditions, including sepsis, chronic obstructive pulmonary disease, heart failure, and cancer [<xref ref-type="bibr" rid="B1-ijms-20-01962">1</xref>,<xref ref-type="bibr" rid="B2-ijms-20-01962">2</xref>]. Notably, cachexia is the leading cause of death for 20%–40% of cancer patients [<xref ref-type="bibr" rid="B3-ijms-20-01962">3</xref>], and affects around 60% of patients when all cancer types are considered [<xref ref-type="bibr" rid="B4-ijms-20-01962">4</xref>]. Cachexia is more prevalent in gastric or pancreatic cancer, as up to 80% of patients may develop the syndrome [<xref ref-type="bibr" rid="B5-ijms-20-01962">5</xref>,<xref ref-type="bibr" rid="B6-ijms-20-01962">6</xref>]. </p>
<p>Cachexia occurs in all cancer stages, and is associated with poor prognosis, decreased treatment tolerance, and a significant reduction in quality of life [<xref ref-type="bibr" rid="B7-ijms-20-01962">7</xref>]. International consensus defines the diagnostic for cancer cachexia based on weight loss greater than 5% over six months, or weight loss greater than 2% in individuals with a body mass index lower than 20 kg/m<sup>2</sup> or with sarcopenia [<xref ref-type="bibr" rid="B7-ijms-20-01962">7</xref>]. Other features associated with cancer cachexia are a reduction in food intake, an increase of systemic inflammation markers like C-reactive protein, and decreased response to chemotherapy [<xref ref-type="bibr" rid="B7-ijms-20-01962">7</xref>]. These features may increase surgical risk in cachectic patients [<xref ref-type="bibr" rid="B7-ijms-20-01962">7</xref>,<xref ref-type="bibr" rid="B8-ijms-20-01962">8</xref>]. Thus, the conservation of lean body mass is critical for cancer patients’ survival. Although there are some advances in therapeutic strategies for muscle wasting in cancer cachexia (reviewed in [<xref ref-type="bibr" rid="B4-ijms-20-01962">4</xref>]), effective targets to treat the syndrome are still lacking. </p>
<p>Many studies have been conducted to identify the molecular mechanisms related to muscle wasting in cancer cachexia. These studies have already lead to important advances through the recognition of the association between cachexia and high levels of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor alpha (TNF), and interferon gamma (IFN) [<xref ref-type="bibr" rid="B9-ijms-20-01962">9</xref>,<xref ref-type="bibr" rid="B10-ijms-20-01962">10</xref>,<xref ref-type="bibr" rid="B11-ijms-20-01962">11</xref>,<xref ref-type="bibr" rid="B12-ijms-20-01962">12</xref>,<xref ref-type="bibr" rid="B13-ijms-20-01962">13</xref>,<xref ref-type="bibr" rid="B14-ijms-20-01962">14</xref>]. These cytokines activate different molecular axes in skeletal muscle cells by the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), signal transducer and activator of transcription (STAT), MAP kinase family (MAPKs), and activator protein 1 (AP1) [<xref ref-type="bibr" rid="B15-ijms-20-01962">15</xref>,<xref ref-type="bibr" rid="B16-ijms-20-01962">16</xref>,<xref ref-type="bibr" rid="B17-ijms-20-01962">17</xref>,<xref ref-type="bibr" rid="B18-ijms-20-01962">18</xref>]. Signal transductions to NF-κB and STAT transcription factors have key roles, especially in altering three major effector biological systems: the ubiquitin–proteasome system, the IGF1–AKT–FOXO signaling pathway, and the autophagy–lysosome system [<xref ref-type="bibr" rid="B19-ijms-20-01962">19</xref>,<xref ref-type="bibr" rid="B20-ijms-20-01962">20</xref>,<xref ref-type="bibr" rid="B21-ijms-20-01962">21</xref>]. Together, these systems contribute to an imbalance between protein synthesis and degradation that results in loss of muscle mass and function [<xref ref-type="bibr" rid="B19-ijms-20-01962">19</xref>,<xref ref-type="bibr" rid="B20-ijms-20-01962">20</xref>,<xref ref-type="bibr" rid="B21-ijms-20-01962">21</xref>]. Given the complexity of these processes leading to muscle atrophy, the identification and characterization of new genes and signaling pathways based on global analysis will likely contribute to the understanding of the underlying molecular mechanisms of muscle wasting in cancer cachexia. </p>
<p>In fact, global gene expression studies of muscle wasting conditions, such as glucocorticoid treatment, immobilization, unloading, diabetes, sarcopenia, starvation, and denervation [<xref ref-type="bibr" rid="B22-ijms-20-01962">22</xref>,<xref ref-type="bibr" rid="B23-ijms-20-01962">23</xref>,<xref ref-type="bibr" rid="B24-ijms-20-01962">24</xref>,<xref ref-type="bibr" rid="B25-ijms-20-01962">25</xref>,<xref ref-type="bibr" rid="B26-ijms-20-01962">26</xref>,<xref ref-type="bibr" rid="B27-ijms-20-01962">27</xref>], have helped to shed light on the molecular mechanisms of muscle atrophy, including the identification of new potential biomarkers of cancer cachexia [<xref ref-type="bibr" rid="B28-ijms-20-01962">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-01962">29</xref>]. The identification of microRNAs has also broadened the knowledge about global gene expression regulation in conditions that induce skeletal muscle atrophy [<xref ref-type="bibr" rid="B30-ijms-20-01962">30</xref>,<xref ref-type="bibr" rid="B31-ijms-20-01962">31</xref>,<xref ref-type="bibr" rid="B32-ijms-20-01962">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-01962">33</xref>], including cancer cachexia [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>]. However, there is a lack of integration of global microRNA and mRNA expression data from the same set of muscle samples in previous cancer cachexia studies [<xref ref-type="bibr" rid="B28-ijms-20-01962">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-01962">29</xref>,<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>,<xref ref-type="bibr" rid="B36-ijms-20-01962">36</xref>,<xref ref-type="bibr" rid="B37-ijms-20-01962">37</xref>,<xref ref-type="bibr" rid="B38-ijms-20-01962">38</xref>,<xref ref-type="bibr" rid="B39-ijms-20-01962">39</xref>,<xref ref-type="bibr" rid="B40-ijms-20-01962">40</xref>,<xref ref-type="bibr" rid="B41-ijms-20-01962">41</xref>]. Furthermore, to our knowledge, no study has integrated the most relevant microRNA and mRNA data available in the literature. Such integrative strategies are important for identifying the functional significance of key deregulated genes, microRNAs, and molecular pathways involved in muscle wasting in cachexia.</p>
<p>Moreover, the high diversity among human and animal models with cancer cachexia, the complexity of the syndrome, the difficulties in recruiting patients for studies, and the heterogeneity of cancer cells and muscle phenotypes leads to low translatability from experimental systems to clinical practice [<xref ref-type="bibr" rid="B42-ijms-20-01962">42</xref>]. We performed a systematic integration of validated gene expression data derived from global mRNA and microRNA expression profiles in muscle wasting in cancer cachexia, to capture the most relevant microRNA-regulated networks across multiple human and rodent studies. Our analysis identified new molecular pathways potentially involved in skeletal muscle atrophy in cancer cachexia. These data have also proven useful for identifying new, potentially molecular-targeted treatment strategies for the syndrome.</p>
</sec>
<sec id="sec2-ijms-20-01962" sec-type="results">
<title>2. Results </title>
<sec id="sec2dot1-ijms-20-01962">
<title>2.1. Study Selection and Characteristics</title>
<p>The meta-analysis resulted in nine studies reporting skeletal muscle gene expression data in cancer cachexia [<xref ref-type="bibr" rid="B28-ijms-20-01962">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-01962">29</xref>,<xref ref-type="bibr" rid="B36-ijms-20-01962">36</xref>,<xref ref-type="bibr" rid="B37-ijms-20-01962">37</xref>,<xref ref-type="bibr" rid="B38-ijms-20-01962">38</xref>,<xref ref-type="bibr" rid="B39-ijms-20-01962">39</xref>,<xref ref-type="bibr" rid="B40-ijms-20-01962">40</xref>,<xref ref-type="bibr" rid="B41-ijms-20-01962">41</xref>,<xref ref-type="bibr" rid="B43-ijms-20-01962">43</xref>]. The process to select the studies is summarized in <xref ref-type="fig" rid="ijms-20-01962-f001">Figure 1</xref>. We present the description of publicly available cancer cachexia studies included in the meta-analysis in <xref ref-type="table" rid="ijms-20-01962-t001">Table 1</xref>. These studies report muscle gene expression data from patients and mouse models with different cancer types (gastrointestinal, colon, and pancreatic cancers). The expression data were obtained in distinct muscles: three studies present data from the gastrocnemius, three from the quadriceps, one from the rectus abdominis, one from the biceps femoris, and one from the extensor digitorum longus. This variability in skeletal muscle phenotype expands the transcript profiles, increasing the number of possibilities for identification of key common molecular pathways in muscle wasting triggered by different cancer types. Most of these studies were performed in a limited number of samples (3–21 samples/group), and therefore, a comprehensive and integrative analysis of these data may reveal new molecular components that are not identified when these studies are analyzed individually.</p>
</sec>
<sec id="sec2dot2-ijms-20-01962">
<title>2.2. Validated Data Selection of Differentially Expressed Genes in Cancer Cachexia</title>
<p>We filtered the genes with differential expression that were validated by western blotting and/or quantitative reverse transcription polymerase chain reaction (RT-qPCR) techniques. This strategy allowed us to use the transcripts selected as more relevant by the authors in the global analysis, and therefore, specifically investigate those that may be directly related to molecular alterations in muscle wasting in cancer cachexia. These studies reported, excluding duplicates, 52 differentially expressed genes in 59 samples of muscle tissue from patients and rodent models of cancer cachexia. A list of the validated data for differentially expressed genes in cancer cachexia, with their respective functions and location, is summarized in <xref ref-type="table" rid="ijms-20-01962-t002">Table 2</xref> and <xref ref-type="app" rid="app1-ijms-20-01962">Table S1</xref>. We highlight that the atrogenes <italic>Fbxo32</italic> and <italic>Trim63</italic> appeared in six out of the nine selected studies, and <italic>Cebpd</italic> and <italic>Cxcl12</italic> are dysregulated in two studies. Notably, 10 over-expressed genes (<italic>Comp, Mmp3, Adipoq, Angptl7, Fgg, Hp, Mstn, Saa1, Serpina3n,</italic> and <italic>Cxcl12</italic>) are translated into secreted proteins, and therefore, can be further explored as potential cancer cachexia biomarkers. </p>
</sec>
<sec id="sec2dot3-ijms-20-01962">
<title>2.3. Gene Ontology Enrichment Analysis of Differentially Expressed Genes in Muscle Wasting in Cancer Cachexia</title>
<p>Gene ontology (GO) analysis shows information on the biological role of differentially expressed genes involved in muscle wasting in cancer cachexia. We used gene ontology hierarchically structured categories to identify proteins encoded by the up- and down-expressed genes. This analysis revealed over-represented GO categories of biological processes that included structural and development genes (e.g., negative regulation of muscle hypertrophy, anatomical structure morphogenesis, epithelial cell proliferation, muscle organ development, muscle cell differentiation, and tissue development), metabolic process, acute-phase response, and apoptotic process. Other relevant terms enriched in our dataset included response to insulin and response to hormone stimulus. The statistically significant enriched GO terms are shown in <xref ref-type="fig" rid="ijms-20-01962-f002">Figure 2</xref>.</p>
</sec>
<sec id="sec2dot4-ijms-20-01962">
<title>2.4. Protein–Protein Interaction Network in Muscle Wasting in Cancer Cachexia</title>
<p>The integrated protein–protein interaction (PPI) network shows a higher number of interactions between proteins of the inflammatory response, catabolism and anabolism, fat metabolism, apoptotic process, and transcriptional control. Complex interactome analysis of deregulated genes in cancer cachexia, with respective functional annotations, is illustrated in <xref ref-type="fig" rid="ijms-20-01962-f003">Figure 3</xref>.</p>
</sec>
<sec id="sec2dot5-ijms-20-01962">
<title>2.5. Identification of New Potential microRNA-Regulated Networks in Muscle Wasting in Cancer Cachexia</title>
<p>The miRNA-mRNA target prediction identified 3150 non-validated and 98 validated interactions (<xref ref-type="app" rid="app1-ijms-20-01962">Tables S2 and S3</xref>). The validated interactions were used to construct a microRNA-target mRNA interaction network for up- and down-regulated genes (<xref ref-type="fig" rid="ijms-20-01962-f004">Figure 4</xref>A,B, respectively). Networks were constructed with our list of microRNAs predicted in silico as targeting the mRNAs retrieved by our meta-analysis, and with microRNAs found as deregulated in two previous microRNAs studies on muscle wasting in cancer cachexia [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>] (<xref ref-type="app" rid="app1-ijms-20-01962">Table S2</xref>). Interestingly, the intersection of all the microRNA data showed that our list of predicted microRNAs shares five microRNAs with one study [<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>] (miR-27a, miR-27b, miR-140, miR-24, and miR-15) and the microRNA miR-199 with another [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>] (<xref ref-type="fig" rid="ijms-20-01962-f005">Figure 5</xref>A). </p>
<p>Next, we predicted genes targeted by the differentially expressed microRNAs by both these previous studies. These genes were further compared with the list of 52 deregulated genes identified in our meta-analysis. We found a total of five shared transcripts (<italic>Cav1</italic>, <italic>Cxcl12</italic>, <italic>Foxo1</italic>, <italic>Mef2c</italic>, and <italic>Junb</italic>) (<xref ref-type="fig" rid="ijms-20-01962-f005">Figure 5</xref>B), and most importantly, these five transcripts revealed seven new microRNA-mRNA interactions in muscle wasting in cancer cachexia (miR-27a/<italic>Foxo1</italic>, miR-27a/<italic>Mef2c</italic>, miR-27b/<italic>Cxcl12</italic>, miR-27b/<italic>Mef2c</italic>, miR-140/<italic>Cxcl12</italic>, miR-199a/<italic>Cav1</italic>, and miR-199a/<italic>Junb</italic>) (<xref ref-type="table" rid="ijms-20-01962-t003">Table 3</xref>). Notably, three interactions—miR-27a/<italic>Foxo1</italic>, miR-140/<italic>Cxcl12</italic>, and miR-199a/<italic>Cav1</italic>—showed an opposite direction of expression between microRNAs (identified in the previous studies [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>]) and mRNAs (identified in the meta-analysis) (<xref ref-type="table" rid="ijms-20-01962-t003">Table 3</xref>).</p>
</sec>
<sec id="sec2dot6-ijms-20-01962">
<title>2.6. Identification of Potential Target Agents for the Treatment of Muscle Wasting in Cancer Cachexia</title>
<p>Interestingly, Drug–Gene Interaction Database (DGIdb) data revealed <italic>ADIPOQ</italic>, <italic>CAMK2B</italic>, <italic>COMP</italic>, <italic>CXCL12</italic>, and <italic>MSTN</italic> as drug-targetable genes, using chemical compounds such as Spironolactone, Fenofibrate, Nevirapine, Mibefradil, Nifedipine, Nisoldipine, Tadalafil, Tinzaparin Sodium, and Stamulumab (<xref ref-type="table" rid="ijms-20-01962-t004">Table 4</xref>). The above drugs have been demonstrated as clinically useful in Type 2 diabetes mellitus, cardiovascular disease, HIV infection, smooth muscle, cardiac muscle, breast cancer, and myopathies [<xref ref-type="bibr" rid="B44-ijms-20-01962">44</xref>,<xref ref-type="bibr" rid="B45-ijms-20-01962">45</xref>,<xref ref-type="bibr" rid="B46-ijms-20-01962">46</xref>,<xref ref-type="bibr" rid="B47-ijms-20-01962">47</xref>,<xref ref-type="bibr" rid="B48-ijms-20-01962">48</xref>,<xref ref-type="bibr" rid="B49-ijms-20-01962">49</xref>,<xref ref-type="bibr" rid="B50-ijms-20-01962">50</xref>,<xref ref-type="bibr" rid="B51-ijms-20-01962">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-01962">52</xref>,<xref ref-type="bibr" rid="B53-ijms-20-01962">53</xref>]. Outstandingly, the potential drugs found here have not been tested yet for the treatment of muscle wasting in cancer cachexia.</p>
</sec>
</sec>
<sec id="sec3-ijms-20-01962" sec-type="discussion">
<title>3. Discussion</title>
<p>Researchers have conducted several studies on molecular mechanisms of muscle wasting in cancer cachexia. However, the complexity of the syndrome and the insufficient knowledge of pathogenic mechanisms hinder the design of effective therapeutic strategies. Most cancer cachexia studies rely on a single, thorough, standardized model or specific cancer types, rarely integrating and comparing their datasets with those from other experimental systems. The present meta-analysis allowed us to select relevant mRNA expression data from different cancer cachexia studies. This is the first study integrating the most relevant literature data from global gene expression profiling studies in muscle wasting in cancer cachexia, in order to find common regulatory networks and molecular pathways. We identify new potential microRNA-regulated gene networks involved in muscle wasting in cancer cachexia (<xref ref-type="scheme" rid="ijms-20-01962-sch001">Scheme 1</xref>). Specifically, our results suggest that microRNA/mRNA interactions miR-27a/<italic>Foxo1</italic>, miR-27a/<italic>Mef2c</italic>, miR-27b/<italic>Cxcl12</italic>, miR-27b/<italic>Mef2c</italic>, miR-140/<italic>Cxcl12</italic>, miR-199a/<italic>Cav1</italic>, and miR-199a/<italic>Junb</italic> may contribute to muscle wasting in cancer cachexia.</p>
<p>Among the 52 deregulated genes identified in our analysis, six of the nine studies included in the meta-analysis have evaluated the expression of <italic>Trim63</italic> and <italic>Fbxo32</italic> as molecular markers of muscle atrophy in cancer cachexia. In 2001, <italic>Trim63</italic> and <italic>Fbxo32</italic> were first identified as two important muscle-specific E3 ubiquitin ligases that are transcriptionally increased in skeletal muscle under atrophy-inducing conditions, making them excellent markers of muscle atrophy [<xref ref-type="bibr" rid="B54-ijms-20-01962">54</xref>]. The transcription of enzymes <italic>Trim63</italic> and <italic>Fbxo32</italic> is dependent on transcriptional factors <italic>FoxO1</italic> and <italic>FoxO</italic>3, which are thought to regulate both the ubiquitin/proteasome [<xref ref-type="bibr" rid="B27-ijms-20-01962">27</xref>] and autophagy [<xref ref-type="bibr" rid="B20-ijms-20-01962">20</xref>,<xref ref-type="bibr" rid="B55-ijms-20-01962">55</xref>,<xref ref-type="bibr" rid="B56-ijms-20-01962">56</xref>] pathways. Interestingly, our enrichment analysis also showed alteration in the regulation of the apoptotic process induced by changes in the expression of <italic>FoxO1</italic>, <italic>BNIP3,</italic> and <italic>GABARAPL1</italic>. These results are in agreement with the fact that skeletal muscle wasting is the result of an imbalance between synthesis and degradation of protein pathways, together with the instability of regenerative capacity and myocyte apoptosis [<xref ref-type="bibr" rid="B57-ijms-20-01962">57</xref>,<xref ref-type="bibr" rid="B58-ijms-20-01962">58</xref>]. </p>
<p>Moreover, we showed miR-145a as a new potential <italic>FoxO1</italic> regulator during muscle wasting in cancer cachexia. Indeed, the increase of miR-145 decreases <italic>FoxO1</italic> expression in metastatic T24T bladder cancer cells [<xref ref-type="bibr" rid="B59-ijms-20-01962">59</xref>]. Conversely, in non-metastatic bladder transitional cell carcinoma T24 cells, miR-145 overexpression inhibited cell growth, which correlates with upregulation of <italic>FoxO1</italic> [<xref ref-type="bibr" rid="B59-ijms-20-01962">59</xref>]. These opposite results are probably associated with different cell types and experimental conditions, raising the necessity to further explore miR-145-<italic>FoxO1</italic>. One of the most important findings of our study was that <italic>FoxO1</italic> is a validated target of the microRNA miR-27a. Besides, Soares et al. [<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>] identified the down-regulation of miR-27a in cancer-cachexia. Although the miR-27a-–<italic>FoxO1</italic> interaction is not validated in skeletal muscle cells, the overexpression of miR-27a in mice with chronic kidney disease attenuated muscle loss, improved grip strength, and decreased the expression of FoxO1, Trim63, and Fbxo32 proteins [<xref ref-type="bibr" rid="B60-ijms-20-01962">60</xref>]. </p>
<p>Besides these molecular markers of muscle atrophy, our meta-analysis also identified <italic>Nr3c1</italic> as down-regulated in the skeletal muscle of cachectic patients with upper gastrointestinal cancer [<xref ref-type="bibr" rid="B29-ijms-20-01962">29</xref>]. <italic>Nr3c1</italic> has a function in the regulation of muscle hypertrophy and strength in response to resistance training [<xref ref-type="bibr" rid="B61-ijms-20-01962">61</xref>]; however, the role of <italic>Nr3c1</italic> in the development of muscle wasting associated with cancer is still unknown. Furthermore, our microRNA target prediction analysis identified nine microRNAs that potentially modulate <italic>Nr3c1</italic> expression, including microRNAs miR-28b and miR-28c. We also identified that the <italic>Nr3c1</italic> transcript is potentially regulated by miR-30e, which is upregulated in the skeletal muscle of <italic>Mstn</italic>-/- mice, and its expression was associated with glycolytic myofiber formation [<xref ref-type="bibr" rid="B62-ijms-20-01962">62</xref>]. Considering that microRNAs miR-28b, miR-28c, and miR-30e potentially target the <italic>Nr3c1</italic> transcript, and that both microRNAs and their target transcripts have important functions previously described in skeletal muscle tissue, our integrative analysis reveals these new microRNA–mRNA interactions as potential targets for future exploratory analysis of muscle wasting in cancer cachexia. </p>
<p>Our prediction analyses also revealed microRNA miR-17 as an important regulator of transcripts, such as <italic>Cxcl12</italic>, <italic>Mef2c</italic>, <italic>Stat3</italic>, and <italic>Cav1</italic>, that are translated into proteins with a role in cancer cachexia. MicroRNA miR-17 is involved in oncogenic events in different cancer types with a high incidence of cachexia (hepatocellular carcinoma [<xref ref-type="bibr" rid="B63-ijms-20-01962">63</xref>], pancreatic cancer [<xref ref-type="bibr" rid="B64-ijms-20-01962">64</xref>], and non-small lung cancer [<xref ref-type="bibr" rid="B65-ijms-20-01962">65</xref>,<xref ref-type="bibr" rid="B66-ijms-20-01962">66</xref>]). Among the miR-17 target genes, <italic>Mef2c</italic> is involved in the regulation of skeletal muscle regeneration and myogenesis (reviewed in Dong et al. [<xref ref-type="bibr" rid="B67-ijms-20-01962">67</xref>]). Also, two studies have identified miR-27b as a regulator of <italic>Mef2c</italic> [<xref ref-type="bibr" rid="B68-ijms-20-01962">68</xref>,<xref ref-type="bibr" rid="B69-ijms-20-01962">69</xref>]; notably, one of these studies shows that miR-27b is involved in the regulation of mitochondrial biogenesis in myocytes by regulating <italic>Mef2c</italic> [<xref ref-type="bibr" rid="B69-ijms-20-01962">69</xref>]. Importantly, miR-27b also negatively regulates myostatin (<italic>Mstn</italic>) to promote satellite cell activation and myoblast proliferation, and to prevent muscle wasting [<xref ref-type="bibr" rid="B70-ijms-20-01962">70</xref>]. <italic>Mstn</italic>, a member of the <italic>TGFβ</italic> superfamily of growth factors, is a highly conserved negative regulator of skeletal muscle mass upregulated in muscle wasting conditions, including cancer cachexia [<xref ref-type="bibr" rid="B37-ijms-20-01962">37</xref>,<xref ref-type="bibr" rid="B71-ijms-20-01962">71</xref>,<xref ref-type="bibr" rid="B72-ijms-20-01962">72</xref>]. Accordingly, <italic>Mstn</italic> deficiency increase skeletal muscle mass and strength and counterattacks muscle wasting conditions [<xref ref-type="bibr" rid="B73-ijms-20-01962">73</xref>]. Several studies have demonstrated the therapeutic potential of <italic>Mstn</italic> inhibition under muscle wasting conditions as cancer [<xref ref-type="bibr" rid="B74-ijms-20-01962">74</xref>,<xref ref-type="bibr" rid="B75-ijms-20-01962">75</xref>]; consequently, the identification of <italic>Mstn</italic> as a putative target of miR-27b has potential therapeutic and biological implications in muscle wasting conditions. </p>
<p>Moreover, our results showed that the drug Stamulumab (MYO-029), known as a potential <italic>MSTN</italic> inhibitor, was previously tested in clinical studies of subjects with myopathies. This trial showed a potential increase in the muscle size of the subjects, but the researchers observed no improvements in muscle strength or function [<xref ref-type="bibr" rid="B52-ijms-20-01962">52</xref>,<xref ref-type="bibr" rid="B53-ijms-20-01962">53</xref>]. Considering that there are no studies testing MYO-029 on cancer cachexia, further studies are needed to demonstrate whether this drug may improve muscle mass and function in this syndrome. </p>
<p>It is also important to highlight that our enrichment analysis identified genes associated with the acute-phase response. Systemic inflammation is a hallmark of cancer cachexia, and this inflammatory response is the main driving force that leads to the metabolic alterations observed in cancer patients [<xref ref-type="bibr" rid="B7-ijms-20-01962">7</xref>]. The literature points out several origins of inflammation, including tumor cells and activated immune cells that release cytokines, chemokines, and other inflammatory mediators [<xref ref-type="bibr" rid="B76-ijms-20-01962">76</xref>]. <italic>Cxcl12</italic> was one of the top transcripts, with the highest number of microRNA interactions identified in our meta-analysis (nine interactions in total). The identification of microRNAs that target <italic>CXCL12</italic> is important, because it has been demonstrated that <italic>CXCR4</italic> pathway is consistently downregulated in skeletal muscles from mice and patients with cancer-associated cachexia, and the activation of the <italic>Cxcl12/Cxcr4</italic> pathway protects muscle from wasting in mice with the syndrome [<xref ref-type="bibr" rid="B43-ijms-20-01962">43</xref>]. This inflammatory chemokine is also relevant in skeletal muscle regeneration by increasing the activity of metalloproteases, which are crucial to the remodeling of the extracellular matrix [<xref ref-type="bibr" rid="B77-ijms-20-01962">77</xref>]. Our results also show protein–protein interactions of <italic>Cxcl12</italic> with the metalloprotease <italic>Mmp</italic>, suggesting that this interaction could affect muscle regeneration and extracellular matrix remodeling in cancer cachexia. Indeed, we identified that miR-27b and miR-140 are two potential microRNAs involved in <italic>Cxcl12</italic> regulation. Importantly, it has been previously demonstrated that miR-140 transfection decreases <italic>Cxcl12</italic> expression and release in human airway smooth muscle cells, with a reduction in inflammatory response [<xref ref-type="bibr" rid="B78-ijms-20-01962">78</xref>]. Thus, our data also suggest a response that compromises inflammatory response through the mir-140/<italic>Cxcl12</italic> axis in muscle wasting during cancer cachexia.</p>
<p>Furthermore, among the acute phase response genes identified by ontology analysis, <italic>Stat3</italic> was the most notorious factor of our interaction network. The role of this transcriptional factor is widely studied in cancer cachexia. The increase of interleukin-6 in cachectic patients triggers the activation of JAK (Janus kinase), with consequent STAT3 phosphorylation that acts at the nucleus; this leads to transcription activation of several genes associated with skeletal muscle cells growth, atrophy, proliferation, differentiation, survival, and apoptosis [<xref ref-type="bibr" rid="B38-ijms-20-01962">38</xref>,<xref ref-type="bibr" rid="B79-ijms-20-01962">79</xref>,<xref ref-type="bibr" rid="B80-ijms-20-01962">80</xref>]. Moreover, STAT3 contributes to cancer cachexia enhancing tumorigenesis, metastasis, and immune suppression, mostly in tumors associated with a high prevalence of cachexia [<xref ref-type="bibr" rid="B80-ijms-20-01962">80</xref>]. Given the diversity of activated genes obtained through the JAK/STAT pathway, it is essential to better characterize <italic>Stat3</italic> downstream target genes in the skeletal muscle cells in wasting conditions. The SOCS3 is a classic inhibitor of the JAK/STAT pathway and several cytokines, and pathogenic mediators induce the expression of SOCS3, which acts in a negative feedback loop to further inhibit signal transduction [<xref ref-type="bibr" rid="B81-ijms-20-01962">81</xref>,<xref ref-type="bibr" rid="B82-ijms-20-01962">82</xref>]. In a murine model of pancreatic cancer cachexia, the JAK/STAT/SOCS3-dependent intracellular pathway plays an essential role in pathogenesis, since its pharmacological inhibition attenuates cachexia progression in a lethal pancreatic cancer model [<xref ref-type="bibr" rid="B39-ijms-20-01962">39</xref>].</p>
<p>Our predicted molecular network also revealed a <italic>Stat3/Junb</italic> interaction. <italic>Junb</italic> is a transcriptional factor that regulates gene expression on multiple levels [<xref ref-type="bibr" rid="B83-ijms-20-01962">83</xref>], but the functionality of this <italic>Stat3/Junb</italic> interaction deserves future study in relation to cancer cachexia. Our study identified miR-199a as a potential microRNA that modulates <italic>Junb</italic> expression in muscle wasting in this syndrome. In addition, we found an inverse correlation between miR-199a and <italic>Cav1</italic> expression. Since many inflammatory mediators are activated in cancer cachexia, and the miR199a/<italic>Cav1</italic> axis was previously described in several chronic inflammatory lung diseases as an important regulatory pathway [<xref ref-type="bibr" rid="B84-ijms-20-01962">84</xref>], this axis should also be considered for further investigations in muscle wasting in cancer cachexia.</p>
<p>The main contribution of the present investigation is that we identify new potential microRNA-regulated mRNAs in cancer cachexia. Nevertheless, our study has some limitations due to the nature of our analysis, which consists of the reuse of transcriptomic data from different studies and in silico analysis. Further studies are needed to validate the microRNA–mRNA interactions described herein, as well as to validate the efficiency of the identified potential drugs. Furthermore, the deregulated genes selected in our analysis were restricted to those further validated by RT-qPCR or Western Blot. We considered this strategy to increase the possibility of rescuing truly deregulated targets, or with a potential impact on protein levels. Finally, due to the small number of studies evaluating muscle transcriptome of patients with cachexia, we used data from humans and mice together to identify a higher range of transcripts.</p>
<p>In conclusion, we identified new microRNA–mRNA interactions, such as miR-27a/<italic>Foxo1</italic>, miR-27a/<italic>Mef2c</italic>, miR-27b/<italic>Cxcl12</italic>, miR-27b/<italic>Mef2c</italic>, miR-140/<italic>Cxcl12</italic>, miR-199a/<italic>Cav1</italic>, and miR-199a/<italic>Junb</italic>, that may contribute to muscle wasting in cancer cachexia. Finally, we found drugs targeting <italic>MSTN</italic>, <italic>CXCL12</italic>, and <italic>CAMK2B</italic>, which may be considered for the development of novel therapeutic strategies for cancer-related cachexia.</p>
</sec>
<sec id="sec4-ijms-20-01962" sec-type="methods">
<title>4. Methods</title>
<sec id="sec4dot1-ijms-20-01962">
<title>4.1. Meta-Analysis of Global Gene Expression Data in Muscle Wasting in Cancer Cachexia</title>
<p>We performed a meta-analysis design following the stages of the PRISMA Statement [<xref ref-type="bibr" rid="B85-ijms-20-01962">85</xref>] (<xref ref-type="fig" rid="ijms-20-01962-f001">Figure 1</xref>), by searching PubMed (<uri xlink:href="http://www.ncbi.nlm.nih.gov/pubmed">http://www.ncbi.nlm.nih.gov/pubmed</uri>) to find the collection of previously published gene expression data of skeletal muscles in cancer cachexia. The keywords used were: “cancer cachexia AND global gene expression”, “cancer cachexia AND transcriptome”, “cancer cachexia AND transcriptomics”, “cancer cachexia AND microarray”, and “cancer cachexia AND RNAseq”. These meta-analysis searches comprised studies published between January 2005 and February 2019. Our inclusion criteria were (1) gene expression data in muscle samples of patients with cancer cachexia or animal models of cancer cachexia, (2) all types of cancer were considered, (3) all types of muscle were considered, (4) the inclusion of normal tissues for comparison, (5) all gene expression analysis platforms were considered, and (6) only data further validated by RT-qPCR or Western Blot were included for the integrative analyses. Our exclusion criteria were (1) non-muscle samples, (2) treatment before molecular genetic analysis, and (3) review studies. The deregulated genes reported in selected studies were further used for bioinformatics prediction of microRNAs as potential regulators of gene expression, as described below.</p>
</sec>
<sec id="sec4dot2-ijms-20-01962">
<title>4.2. Meta-Analysis of Global microRNA Expression Data in Muscle Wasting in Cancer Cachexia</title>
<p>To search previously published global microRNA expression data for skeletal muscle in cancer cachexia, we used the following keywords in PubMed: “cancer cachexia AND global microRNA expression”, “cancer cachexia AND microRNome”, and “cancer cachexia AND microRNA profiling”. This search only retrieved four studies: (1) microRNA profiling in adipocyte lipolysis [<xref ref-type="bibr" rid="B86-ijms-20-01962">86</xref>]; (2) integrative microRNAs and mRNAs expression analysis during skeletal muscle wasting in cardiac cachexia [<xref ref-type="bibr" rid="B87-ijms-20-01962">87</xref>]; (3) microRNA profiling in muscle wasting during catabolic conditions, including cancer cachexia [<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>]; and (4) microRNA profiling from human skeletal muscle in cancer cachexia [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>]. The microRNA data of these last two studies were included for the identification of regulatory networks, in addition to the microRNAs that were identified in an in silico, mRNA-based target prediction described subsequently.</p>
</sec>
<sec id="sec4dot3-ijms-20-01962">
<title>4.3. Identification of Muscle microRNAs as Potential Modulators of Deregulated Genes in Cancer Cachexia</title>
<p>The deregulated genes identified in our meta-analysis were used for microRNA prediction by multiple algorithms (TargetScan [<xref ref-type="bibr" rid="B88-ijms-20-01962">88</xref>], MiRTarBase [<xref ref-type="bibr" rid="B89-ijms-20-01962">89</xref>], and miRWalk [<xref ref-type="bibr" rid="B90-ijms-20-01962">90</xref>]) to identify potential regulators (predicted and validated interactions) of the expressed genes in cancer cachexia. Next, to generate the interaction networks, we filtered all microRNAs found by these computational tools, considering only those identified by MiRTarBase as presenting the “reporter assay” as a validation method. We selected MiRTarBase [<xref ref-type="bibr" rid="B89-ijms-20-01962">89</xref>] due to its different validation methods of interaction between mRNAs and microRNAs, ranging from strong to weak evidence of interaction (accordingly, “reporter assay” has the strongest evidence of microRNA–target gene interaction). We also used MiRTarBase to identify microRNA-target transcripts from global microRNA expression in cancer cachexia studies [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>]. The deregulated genes were used to identify over-represented gene ontology categories of biological processes with the Gene Ontology Consortium tool, powered by PANTHER v11.0 [<xref ref-type="bibr" rid="B91-ijms-20-01962">91</xref>,<xref ref-type="bibr" rid="B92-ijms-20-01962">92</xref>,<xref ref-type="bibr" rid="B93-ijms-20-01962">93</xref>] (available at <uri xlink:href="http://www.pantherdb.org/">http://www.pantherdb.org/</uri>). We considered the GO categories with <italic>p</italic>-value ≤ 0.05 to be significant. The UniProtKB database (available at <uri xlink:href="http://www.uniprot.org/">http://www.uniprot.org/</uri>) was used to access functional information of components identified through the meta-analysis. Protein–protein interaction (PPI) networks were then generated using Metasearch STRING v10.5.1 [<xref ref-type="bibr" rid="B94-ijms-20-01962">94</xref>,<xref ref-type="bibr" rid="B95-ijms-20-01962">95</xref>]. Visualization and annotation data of PPI and microRNA-gene interaction networks were generated using Cytoscape v3.4.0 [<xref ref-type="bibr" rid="B96-ijms-20-01962">96</xref>].</p>
</sec>
<sec id="sec4dot4-ijms-20-01962">
<title>4.4. Identification of Candidate Drug Targets Based on microRNA-Regulated Networks in Cancer Cachexia</title>
<p>We used the Drug–Gene Interaction Database (DGIdb), a database and web interface for finding known and potential drug–gene relationships. Genes were defined by Entrez Gene and Ensembl and were matched with genes from drug–gene interactions and druggable gene categories. The drugs were defined by searching PubChem, and were then matched with drugs from drug–gene interaction data. The source guide to pharmacology interaction was obtained from the DrugBank [<xref ref-type="bibr" rid="B97-ijms-20-01962">97</xref>,<xref ref-type="bibr" rid="B98-ijms-20-01962">98</xref>].</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We wish to acknowledge Vanessa M. Lima and João M. Barguil from the University of São Paulo for helping us with comments that improved our manuscript.</p>
</ack>
<app-group>
<app id="app1-ijms-20-01962">
<title>Supplementary Materials</title>
<p>Supplementary materials can be found at <uri xlink:href="https://www.mdpi.com/1422-0067/20/8/1962/s1">https://www.mdpi.com/1422-0067/20/8/1962/s1</uri>.</p>
<supplementary-material content-type="local-data" id="ijms-20-01962-s001">
<media xlink:href="ijms-20-01962-s001.zip">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</app>
</app-group>
<notes>
<title>Funding</title>
<p>The following grants supported the development of this study: National Council of Technological and Scientific Development (CNPq 141919/2016-7), São Paulo Research Foundation (FAPESP grants #14/13783-6 and #12/13961-6), and Coordenação de Aperfeiçoamento Pessoal de Nível Superior-Brasil (CAPES)-grant 88881.187095/2018-01.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflicts of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-01962">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argilés</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Busquets</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stemmler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>López-Soriano</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Cancer cachexia: Understanding the molecular basis</article-title>
<source/>Nat. Rev. Cancer
          <year>2014</year>
<volume>14</volume>
<fpage>754</fpage>
<lpage>762</lpage>
<pub-id pub-id-type="doi">10.1038/nrc3829</pub-id>
<pub-id pub-id-type="pmid">25291291</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-01962">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holecek</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Muscle wasting in animal models of severe illness</article-title>
<source/>Int. J. Exp. Pathol.
          <year>2012</year>
<volume>93</volume>
<fpage>157</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2613.2012.00812.x</pub-id>
<pub-id pub-id-type="pmid">22564195</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-01962">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hauser</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Stockler</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Tattersall</surname>
<given-names>M.H.N.</given-names>
</name>
</person-group>
<article-title>Prognostic factors in patients with recently diagnosed incurable cancer: A systematic review</article-title>
<source/>Support. Care Cancer
          <year>2006</year>
<volume>14</volume>
<fpage>999</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1007/s00520-006-0079-9</pub-id>
<pub-id pub-id-type="pmid">16708213</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-01962">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laviano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meguid</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Inui</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muscaritoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rossi-Fanelli</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself</article-title>
<source/>Nat. Clin. Pract. Oncol.
          <year>2005</year>
<volume>2</volume>
<fpage>158</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1038/ncponc0112</pub-id>
<pub-id pub-id-type="pmid">16264909</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-01962">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fearon</surname>
<given-names>K.C.H.</given-names>
</name>
</person-group>
<article-title>Cancer cachexia: Developing multimodal therapy for a multidimensional problem</article-title>
<source/>Eur. J. Cancer
          <year>2008</year>
<volume>44</volume>
<fpage>1124</fpage>
<lpage>1132</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejca.2008.02.033</pub-id>
<pub-id pub-id-type="pmid">18375115</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-01962">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tisdale</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Cachexia in cancer patients</article-title>
<source/>Nat. Rev. Cancer
          <year>2002</year>
<volume>3</volume>
<fpage>883</fpage>
<lpage>889</lpage>
<pub-id pub-id-type="doi">10.1038/nrc927</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-01962">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fearon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Strasser</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Anker</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Bosaeus</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bruera</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fainsinger</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Jatoi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Loprinzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mantovani</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Definition and classification of cancer cachexia: An international consensus</article-title>
<source/>Lancet Oncol.
          <year>2011</year>
<volume>12</volume>
<fpage>489</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(10)70218-7</pub-id>
<pub-id pub-id-type="pmid">21296615</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-01962">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morley</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M.-M.G.</given-names>
</name>
</person-group>
<article-title>Cachexia: Pathophysiology and clinical relevance</article-title>
<source/>Am. J. Clin. Nutr.
          <year>2006</year>
<volume>83</volume>
<fpage>735</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="doi">10.1093/ajcn/83.4.735</pub-id>
<pub-id pub-id-type="pmid">16600922</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-01962">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penafuerte</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sirois</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia</article-title>
<source/>Br. J. Cancer
          <year>2016</year>
<volume>114</volume>
<fpage>680</fpage>
<lpage>687</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.2016.3</pub-id>
<pub-id pub-id-type="pmid">26954714</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-01962">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuroda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kanao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Miyajima</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Horiguchi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Interleukin 6 is associated with cachexia in patients with prostate cancer</article-title>
<source/>Urology
          <year>2007</year>
<volume>69</volume>
<fpage>113</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.urology.2006.09.039</pub-id>
<pub-id pub-id-type="pmid">17270630</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-01962">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.-J.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>Y.-J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.-C.</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.-T.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>Y.-S.</given-names>
</name>
</person-group>
<article-title>Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes</article-title>
<source/>J. Clin. Med.
          <year>2018</year>
<volume>7</volume>
<elocation-id>502</elocation-id>
<pub-id pub-id-type="doi">10.3390/jcm7120502</pub-id>
<pub-id pub-id-type="pmid">30513776</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-01962">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandarian</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Nosacka</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Delitto</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Judge</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Judge</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Ganey</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Jackman</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice</article-title>
<source/>J. Cachexia Sarcopenia Muscle
          <year>2018</year>
<volume>9</volume>
<fpage>1109</fpage>
<lpage>1120</lpage>
<pub-id pub-id-type="doi">10.1002/jcsm.12346</pub-id>
<pub-id pub-id-type="pmid">30270531</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-01962">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldawer</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Georgieff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lundholm</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia</article-title>
<source/>Clin. Physiol.
          <year>1987</year>
<volume>7</volume>
<fpage>263</fpage>
<lpage>274</lpage>
<pub-id pub-id-type="doi">10.1111/j.1475-097X.1987.tb00169.x</pub-id>
<pub-id pub-id-type="pmid">3304809</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-01962">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argilés</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>López-Soriano</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>The role of cytokines in cancer cachexia</article-title>
<source/>Med. Res. Rev.
          <year>1999</year>
<volume>19</volume>
<fpage>223</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1098-1128(199905)19:3&lt;223::AID-MED3&gt;3.0.CO;2-N</pub-id>
<pub-id pub-id-type="pmid">10232651</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-01962">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ait-Ali</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Turquier</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grumolato</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jourdain</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alexandre</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Eiden</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Vaudry</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Anouar</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1 stimulate neuropeptide gene transcription and secretion in adrenochromaffin cells via activation of extracellularly regulated kinase 1/2 and p38 protein kinases, and activator pro</article-title>
<source/>Mol. Endocrinol.
          <year>2004</year>
<volume>18</volume>
<fpage>1721</fpage>
<lpage>1739</lpage>
<pub-id pub-id-type="doi">10.1210/me.2003-0129</pub-id>
<pub-id pub-id-type="pmid">15087472</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-01962">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Faggioni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Targeting interleukin-6 in inflammatory autoimmune diseases and cancers</article-title>
<source/>Pharmacol. Ther.
          <year>2014</year>
<volume>141</volume>
<fpage>125</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.09.004</pub-id>
<pub-id pub-id-type="pmid">24076269</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-01962">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration</article-title>
<source/>J. Biol. Chem.
          <year>2013</year>
<volume>288</volume>
<fpage>1489</fpage>
<lpage>1499</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.419788</pub-id>
<pub-id pub-id-type="pmid">23184935</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-01962">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heinrich</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Behrmann</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Haan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hermanns</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Müller-Newen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schaper</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Principles of interleukin (IL)-6-type cytokine signalling and its regulation</article-title>
<source/>Biochem. J.
          <year>2003</year>
<volume>374</volume>
<fpage>1</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1042/bj20030407</pub-id>
<pub-id pub-id-type="pmid">12773095</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-20-01962">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Lecker</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Ubiquitin-protein ligases in muscle wasting</article-title>
<source/>Int. J. Biochem. Cell Biol.
          <year>2005</year>
<volume>37</volume>
<fpage>2088</fpage>
<lpage>2097</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2004.11.010</pub-id>
<pub-id pub-id-type="pmid">16125112</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-20-01962">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brault</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Schild</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sandri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schiaffino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lecker</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells</article-title>
<source/>Cell Metab.
          <year>2007</year>
<volume>6</volume>
<fpage>472</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2007.11.004</pub-id>
<pub-id pub-id-type="pmid">18054316</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-01962">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samuels</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Tilignac</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Debiton</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Madelmont</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Attaix</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Higher skeletal muscle protein synthesis and lower breakdown after chemotherapy in cachectic mice</article-title>
<source/>Am. J. Physiol. Regul. Integr. Comp. Physiol.
          <year>2001</year>
<volume>281</volume>
<fpage>R133</fpage>
<lpage>R139</lpage>
<pub-id pub-id-type="doi">10.1152/ajpregu.2001.281.1.R133</pub-id>
<pub-id pub-id-type="pmid">11404286</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-01962">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Lecker</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Jagoe</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Navon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2001</year>
<volume>98</volume>
<fpage>14440</fpage>
<lpage>14445</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.251541198</pub-id>
<pub-id pub-id-type="pmid">11717410</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-01962">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevenson</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Giresi</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Koncarevic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kandarian</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<article-title>Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle</article-title>
<source/>J. Physiol.
          <year>2003</year>
<volume>551</volume>
<fpage>33</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2003.044701</pub-id>
<pub-id pub-id-type="pmid">12844509</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-01962">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giresi</surname>
<given-names>P.G.</given-names>
</name>
</person-group>
<article-title>Identification of a molecular signature of sarcopenia</article-title>
<source/>Physiol. Genom.
          <year>2005</year>
<volume>21</volume>
<fpage>253</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1152/physiolgenomics.00249.2004</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-01962">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevenson</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Koncarevic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giresi</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Jackman</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Kandarian</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<article-title>Transcriptional profile of a myotube starvation model of atrophy</article-title>
<source/>J. Appl. Physiol.
          <year>2005</year>
<volume>98</volume>
<fpage>1396</fpage>
<lpage>1406</lpage>
<pub-id pub-id-type="doi">10.1152/japplphysiol.01055.2004</pub-id>
<pub-id pub-id-type="pmid">15608089</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-01962">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasselgren</surname>
<given-names>P.O.</given-names>
</name>
</person-group>
<article-title>Glucocorticoids and muscle catabolism</article-title>
<source/>Curr. Opin. Clin. Nutr. Metab. Care
          <year>1999</year>
<volume>2</volume>
<fpage>201</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1097/00075197-199905000-00002</pub-id>
<pub-id pub-id-type="pmid">10456248</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-01962">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacheck</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hyatt</surname>
<given-names>J.-P.K.</given-names>
</name>
<name>
<surname>Raffaello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jagoe</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Edgerton</surname>
<given-names>V.R.</given-names>
</name>
<name>
<surname>Lecker</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases</article-title>
<source/>FASEB J.
          <year>2007</year>
<volume>21</volume>
<fpage>140</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1096/fj.06-6604com</pub-id>
<pub-id pub-id-type="pmid">17116744</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-01962">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stephens</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Rooyackers</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Skipworth</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Marstrand</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Guttridge</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Lundell</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fearon</surname>
<given-names>K.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia</article-title>
<source/>Genome Med.
          <year>2010</year>
<volume>2</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/gm122</pub-id>
<pub-id pub-id-type="pmid">20193046</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-01962">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallagher</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Skipworth</surname>
<given-names>R.J.E.</given-names>
</name>
<name>
<surname>Husi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Greig</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Timmons</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Fearon</surname>
<given-names>K.C.H.</given-names>
</name>
</person-group>
<article-title>Suppression of skeletal muscle turnover in cancer cachexia: Evidence from the transcriptome in sequential human muscle biopsies</article-title>
<source/>Clin. Cancer Res.
          <year>2012</year>
<volume>18</volume>
<fpage>2817</fpage>
<lpage>2827</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2133</pub-id>
<pub-id pub-id-type="pmid">22452944</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-01962">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Güller</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>MicroRNAs in skeletal muscle: Their role and regulation in development, disease and function</article-title>
<source/>J. Physiol.
          <year>2010</year>
<volume>588</volume>
<fpage>4075</fpage>
<lpage>4087</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2010.194175</pub-id>
<pub-id pub-id-type="pmid">20724363</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-01962">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberg</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Kunkel</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>miRNAS in normal and diseased skeletal muscle</article-title>
<source/>J. Cell. Mol. Med.
          <year>2009</year>
<volume>13</volume>
<fpage>2</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00524.x</pub-id>
<pub-id pub-id-type="pmid">19175696</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-01962">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberg</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Eran</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nishino</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Moggio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lamperti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Amato</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Lidov</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>North</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>Mitrani-Rosenbaum</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinctive patterns of microRNA expression in primary muscular disorders</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>17016</fpage>
<lpage>17021</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0708115104</pub-id>
<pub-id pub-id-type="pmid">17942673</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-01962">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van de Worp</surname>
<given-names>W.R.P.H.</given-names>
</name>
<name>
<surname>Theys</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van Helvoort</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Langen</surname>
<given-names>R.C.J.</given-names>
</name>
</person-group>
<article-title>Regulation of muscle atrophy by microRNAs: “AtromiRs” as potential target in cachexia</article-title>
<source/>Curr. Opin. Clin. Nutr. Metab. Care
          <year>2018</year>
<volume>21</volume>
<fpage>423</fpage>
<lpage>429</lpage>
<pub-id pub-id-type="doi">10.1097/MCO.0000000000000503</pub-id>
<pub-id pub-id-type="pmid">30198917</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-01962">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narasimhan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stretch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Greiner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bathe</surname>
<given-names>O.F.</given-names>
</name>
<name>
<surname>Baracos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Damaraju</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Small RNAome profiling from human skeletal muscle: Novel miRNAs and their targets associated with cancer cachexia</article-title>
<source/>J. Cachexia Sarcopenia Muscle
          <year>2017</year>
<volume>8</volume>
<fpage>405</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="doi">10.1002/jcsm.12168</pub-id>
<pub-id pub-id-type="pmid">28058815</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-01962">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soares</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Cagnin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chemello</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Silvestrin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Musaro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Pitta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lanfranchi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sandri</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Involvement of microRNAs in the regulation of muscle wasting during catabolic conditions</article-title>
<source/>J. Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<fpage>21909</fpage>
<lpage>21925</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.561845</pub-id>
<pub-id pub-id-type="pmid">24891504</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-01962">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Kulp</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>I.-L.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>E.-C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Frankhouser</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bloomston</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lesinski</surname>
<given-names>G.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia</article-title>
<source/>J. Natl. Cancer Inst.
          <year>2015</year>
<volume>107</volume>
<fpage>djv274</fpage>
<pub-id pub-id-type="doi">10.1093/jnci/djv274</pub-id>
<pub-id pub-id-type="pmid">26464423</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-01962">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Deonarine</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>J.O.</given-names>
</name>
<name>
<surname>Denton</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Feig</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Espeli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kraman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>R.J.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia</article-title>
<source/>J. Exp. Med.
          <year>2013</year>
<volume>210</volume>
<fpage>1137</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20122344</pub-id>
<pub-id pub-id-type="pmid">23712428</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-01962">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonetto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aydogdu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kunzevitzky</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Guttridge</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Khuri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Koniaris</surname>
<given-names>L.G.</given-names>
</name>
<name>
<surname>Zimmers</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e22538</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0022538</pub-id>
<pub-id pub-id-type="pmid">21799891</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-01962">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilabert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Airoldi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hamidi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Moutardier</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Turrini</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Iovanna</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Pancreatic cancer-induced cachexia is Jak2-dependent in mice</article-title>
<source/>J. Cell. Physiol.
          <year>2014</year>
<volume>229</volume>
<fpage>1437</fpage>
<lpage>1443</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.24580</pub-id>
<pub-id pub-id-type="pmid">24648112</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-01962">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shum</surname>
<given-names>A.M.Y.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>D.C.Y.</given-names>
</name>
<name>
<surname>Corley</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>McGill</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Bentley</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Wilkins</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Polly</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Cardiac and skeletal muscles show molecularly distinct responses to cancer cachexia</article-title>
<source/>Physiol. Genom.
          <year>2015</year>
<volume>47</volume>
<fpage>588</fpage>
<lpage>599</lpage>
<pub-id pub-id-type="doi">10.1152/physiolgenomics.00128.2014</pub-id>
<pub-id pub-id-type="pmid">26395599</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-01962">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontes-Oliveira</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Busquets</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fuster</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ametller</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Figueras</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Olivan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Toledo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>López-Soriano</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Demuth</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation–contraction coupling together with additional muscle alterations</article-title>
<source/>Muscle Nerve
          <year>2014</year>
<volume>49</volume>
<fpage>233</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1002/mus.23893</pub-id>
<pub-id pub-id-type="pmid">23649607</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-01962">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penna</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Busquets</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Argilés</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2016</year>
<volume>54</volume>
<fpage>20</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2015.09.002</pub-id>
<pub-id pub-id-type="pmid">26343953</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-01962">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinelli</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Olivari</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Re Cecconi</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Talamini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ottoboni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lecker</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Stretch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baracos</surname>
<given-names>V.E.</given-names>
</name>
<name>
<surname>Bathe</surname>
<given-names>O.F.</given-names>
</name>
<name>
<surname>Resovi</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia</article-title>
<source/>Oncogene
          <year>2016</year>
<volume>35</volume>
<fpage>6212</fpage>
<lpage>6222</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2016.153</pub-id>
<pub-id pub-id-type="pmid">27212031</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-01962">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takebayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aso</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy</article-title>
<source/>Metabolism
          <year>2006</year>
<volume>55</volume>
<fpage>1645</fpage>
<lpage>1652</lpage>
<pub-id pub-id-type="doi">10.1016/j.metabol.2006.07.025</pub-id>
<pub-id pub-id-type="pmid">17142138</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-20-01962">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiuge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tenenbaum</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Benderly</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kumada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fisman</surname>
<given-names>E.Z.</given-names>
</name>
<name>
<surname>Tanne</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Matas</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hibuse</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level</article-title>
<source/>Arterioscler. Thromb. Vasc. Biol.
          <year>2007</year>
<volume>27</volume>
<fpage>635</fpage>
<lpage>641</lpage>
<pub-id pub-id-type="doi">10.1161/01.ATV.0000256469.06782.d5</pub-id>
<pub-id pub-id-type="pmid">17194889</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-20-01962">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petit</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Duong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Masson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Buisson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duvillard</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bour</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Brindisi</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Galland</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guiguet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gambert</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors</article-title>
<source/>Eur. J. Clin. Investig.
          <year>2004</year>
<volume>34</volume>
<fpage>569</fpage>
<lpage>575</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2362.2004.01379.x</pub-id>
<pub-id pub-id-type="pmid">15305892</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-01962">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Cribbs</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Perez-Reyes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hanck</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Mibefradil block of cloned T-type calcium channels</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2000</year>
<volume>295</volume>
<fpage>302</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="pmid">10991994</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-01962">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Soon</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Chua</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Soong</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>A smooth muscle Cav1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine</article-title>
<source/>J. Biol. Chem.
          <year>2007</year>
<volume>282</volume>
<fpage>35133</fpage>
<lpage>35142</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M705478200</pub-id>
<pub-id pub-id-type="pmid">17916557</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-01962">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Splawski</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Timothy</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Sharpe</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Decher</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bloise</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Condouris</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism</article-title>
<source/>Cell
          <year>2004</year>
<volume>119</volume>
<fpage>19</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2004.09.011</pub-id>
<pub-id pub-id-type="pmid">15454078</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-01962">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohamed</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Girgis</surname>
<given-names>N.M.R.</given-names>
</name>
<name>
<surname>Wilcken</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Tinsley</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Gary</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Piazza</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Boeckler</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Abadi</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties</article-title>
<source/>J. Med. Chem.
          <year>2011</year>
<volume>54</volume>
<fpage>495</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1021/jm100842v</pub-id>
<pub-id pub-id-type="pmid">21189023</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-01962">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koo</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>Y.-P.</given-names>
</name>
<name>
<surname>Bay</surname>
<given-names>B.-H.</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>Targeting heparan sulfate proteoglycans in breast cancer treatment</article-title>
<source/>Recent Pat. Anticancer Drug Discov.
          <year>2008</year>
<volume>3</volume>
<fpage>151</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.2174/157489208786242278</pub-id>
<pub-id pub-id-type="pmid">18991783</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-01962">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogdanovich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krag</surname>
<given-names>T.O.B.</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Whittemore</surname>
<given-names>L.-A.</given-names>
</name>
<name>
<surname>Ahima</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Khurana</surname>
<given-names>T.S.</given-names>
</name>
</person-group>
<article-title>Functional improvement of dystrophic muscle by myostatin blockade</article-title>
<source/>Nature
          <year>2002</year>
<volume>420</volume>
<fpage>418</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1038/nature01154</pub-id>
<pub-id pub-id-type="pmid">12459784</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-01962">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Fleckenstein</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Amato</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Barohn</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Bushby</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Flanigan</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Pestronk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tawil</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>G.I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy</article-title>
<source/>Ann. Neurol.
          <year>2008</year>
<volume>63</volume>
<fpage>561</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21338</pub-id>
<pub-id pub-id-type="pmid">18335515</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-01962">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodine</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Latres</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Baumhueter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>Nunez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Poueymirou</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Panaro</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dharmarajan</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of ubiquitin ligases required for skeletal muscle atrophy</article-title>
<source/>Science
          <year>2001</year>
<volume>294</volume>
<fpage>1704</fpage>
<lpage>1708</lpage>
<pub-id pub-id-type="doi">10.1126/science.1065874</pub-id>
<pub-id pub-id-type="pmid">11679633</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-20-01962">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mammucari</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Milan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Romanello</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Masiero</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rudolf</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Del Piccolo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Burden</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Di Lisi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sandri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FoxO3 controls autophagy in skeletal muscle in vivo</article-title>
<source/>Cell Metab.
          <year>2007</year>
<volume>6</volume>
<fpage>458</fpage>
<lpage>471</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2007.11.001</pub-id>
<pub-id pub-id-type="pmid">18054315</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-01962">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sin</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>B.Y.</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>L.W.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-associated apoptotic signalling in senescent heart</article-title>
<source/>J. Physiol.
          <year>2014</year>
<volume>592</volume>
<fpage>2535</fpage>
<lpage>2548</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2014.271387</pub-id>
<pub-id pub-id-type="pmid">24639483</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-20-01962">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penna</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Costamagna</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Camperi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fanzani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chiarpotto</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Cavallini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bonelli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Baccino</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Costelli</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Autophagic degradation contributes to muscle wasting in cancer cachexia</article-title>
<source/>Am. J. Pathol.
          <year>2013</year>
<volume>182</volume>
<fpage>1367</fpage>
<lpage>1378</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2012.12.023</pub-id>
<pub-id pub-id-type="pmid">23395093</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-01962">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argilés</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Busquets</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stemmler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>López-Soriano</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Cachexia and sarcopenia: Mechanisms and potential targets for intervention</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2015</year>
<volume>22</volume>
<fpage>100</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2015.04.003</pub-id>
<pub-id pub-id-type="pmid">25974750</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-01962">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.-R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145</article-title>
<source/>Mol. Cancer Ther.
          <year>2017</year>
<volume>16</volume>
<fpage>924</fpage>
<lpage>935</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0631</pub-id>
<pub-id pub-id-type="pmid">28223425</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-01962">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.H.</given-names>
</name>
</person-group>
<article-title>MicroRNA-23a and MicroRNA-27a Mimic Exercise by Ameliorating CKD-Induced Muscle Atrophy</article-title>
<source/>J. Am. Soc. Nephrol.
          <year>2017</year>
<volume>28</volume>
<fpage>2631</fpage>
<lpage>2640</lpage>
<pub-id pub-id-type="doi">10.1681/ASN.2016111213</pub-id>
<pub-id pub-id-type="pmid">28400445</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-20-01962">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ash</surname>
<given-names>G.I.</given-names>
</name>
<name>
<surname>Kostek</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Angelopoulos</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Clarkson</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Moyna</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Visich</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Zoeller</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>T.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glucocorticoid Receptor (NR3C1) Variants Associate with the Muscle Strength and Size Response to Resistance Training</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0148112</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0148112</pub-id>
<pub-id pub-id-type="pmid">26821164</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-01962">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>miR-30e is negatively regulated by myostatin in skeletal muscle and is functionally related to fiber-type composition</article-title>
<source/>Acta Biochim. Biophys. Sin. (Shanghai)
          <year>2017</year>
<volume>49</volume>
<fpage>392</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1093/abbs/gmx019</pub-id>
<pub-id pub-id-type="pmid">28338991</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-01962">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>MiR-17-92 cluster promotes hepatocarcinogenesis</article-title>
<source/>Carcinogenesis
          <year>2015</year>
<volume>36</volume>
<fpage>1213</fpage>
<lpage>1222</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgv112</pub-id>
<pub-id pub-id-type="pmid">26233958</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-01962">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cioffi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trabulo</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Sanchez-Ripoll</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miranda-Lorenzo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lonardo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dorado</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reis Vieira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Hidalgo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aicher</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells</article-title>
<source/>Gut
          <year>2015</year>
<volume>64</volume>
<fpage>1936</fpage>
<lpage>1948</lpage>
<pub-id pub-id-type="doi">10.1136/gutjnl-2014-308470</pub-id>
<pub-id pub-id-type="pmid">25887381</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-01962">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatterjee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e95716</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0095716</pub-id>
<pub-id pub-id-type="pmid">24755562</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-01962">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer</article-title>
<source/>BMC Cancer
          <year>2015</year>
<volume>15</volume>
<elocation-id>731</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12885-015-1713-z</pub-id>
<pub-id pub-id-type="pmid">26482648</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-01962">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.-Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R.-B.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Q.-D.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>E.-K.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>D.-C.</given-names>
</name>
</person-group>
<article-title>Myocyte enhancer factor 2C and its directly-interacting proteins: A review</article-title>
<source/>Prog. Biophys. Mol. Biol.
          <year>2017</year>
<volume>126</volume>
<fpage>22</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbiomolbio.2017.02.002</pub-id>
<pub-id pub-id-type="pmid">28163053</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-01962">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chinchilla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Daimi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Esteban</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Crist</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Aranega</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>MicroRNA profiling during mouse ventricular maturation: A role for miR-27 modulating Mef2c expression</article-title>
<source/>Cardiovasc. Res.
          <year>2011</year>
<volume>89</volume>
<fpage>98</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvq264</pub-id>
<pub-id pub-id-type="pmid">20736237</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-01962">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>MicroRNA-27b Regulates Mitochondria Biogenesis in Myocytes</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0148532</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0148532</pub-id>
<pub-id pub-id-type="pmid">26849429</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-01962">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McFarlane</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vajjala</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arigela</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lokireddy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bonala</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Manickam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kambadur</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Negative auto-regulation of myostatin expression is mediated by Smad3 and microRNA-27</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e87687</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0087687</pub-id>
<pub-id pub-id-type="pmid">24498167</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-01962">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vernus</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chelh</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cassar-Malek</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gabillard</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Hadj Sassi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Seiliez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bonnieu</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways</article-title>
<source/>Cell. Mol. Life Sci.
          <year>2014</year>
<volume>71</volume>
<fpage>4361</fpage>
<lpage>4371</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-014-1689-x</pub-id>
<pub-id pub-id-type="pmid">25080109</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-01962">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argilés</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Orpí</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Busquets</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>López-Soriano</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Myostatin: More than just a regulator of muscle mass</article-title>
<source/>Drug Discov. Today
          <year>2012</year>
<volume>17</volume>
<fpage>702</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1016/j.drudis.2012.02.001</pub-id>
<pub-id pub-id-type="pmid">22342983</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-01962">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>H.Q.</given-names>
</name>
<name>
<surname>Mitch</surname>
<given-names>W.E.</given-names>
</name>
</person-group>
<article-title>Targeting the myostatin signaling pathway to treat muscle wasting diseases</article-title>
<source/>Curr. Opin. Support. Palliat. Care
          <year>2011</year>
<volume>5</volume>
<fpage>334</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1097/SPC.0b013e32834bddf9</pub-id>
<pub-id pub-id-type="pmid">22025090</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-01962">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders</article-title>
<source/>Curr. Opin. Support. Palliat. Care
          <year>2013</year>
<volume>7</volume>
<fpage>352</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.1097/SPC.0000000000000013</pub-id>
<pub-id pub-id-type="pmid">24157714</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-01962">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallot</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Durieux</surname>
<given-names>A.-C.</given-names>
</name>
<name>
<surname>Castells</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Desgeorges</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Vernus</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Plantureux</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rémond</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jahnke</surname>
<given-names>V.E.</given-names>
</name>
<name>
<surname>Lefai</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dardevet</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Myostatin gene inactivation prevents skeletal muscle wasting in cancer</article-title>
<source/>Cancer Res.
          <year>2014</year>
<volume>74</volume>
<fpage>7344</fpage>
<lpage>7356</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0057</pub-id>
<pub-id pub-id-type="pmid">25336187</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-01962">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argiles</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lopez-Soriano</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Busquets</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Counteracting inflammation: A promising therapy in cachexia</article-title>
<source/>Crit. Rev. Oncog.
          <year>2012</year>
<volume>17</volume>
<fpage>253</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1615/CritRevOncog.v17.i3.30</pub-id>
<pub-id pub-id-type="pmid">22831156</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-01962">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brzoska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kowalewska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Markowska-Zagrajek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kowalski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Archacka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zimowska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grabowska</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Czerwińska</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Czarnecka-Góra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stremińska</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sdf-1 (CXCL12) improves skeletal muscle regeneration via the mobilisation of Cxcr4 and CD34 expressing cells</article-title>
<source/>Biol. Cell
          <year>2012</year>
<volume>104</volume>
<fpage>722</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1111/boc.201200022</pub-id>
<pub-id pub-id-type="pmid">22978573</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-01962">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dileepan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sarver</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Panettieri</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Subramanian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kannan</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>MicroRNA Mediated Chemokine Responses in Human Airway Smooth Muscle Cells</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0150842</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0150842</pub-id>
<pub-id pub-id-type="pmid">26998837</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-01962">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonetto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aydogdu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Puzis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Koniaris</surname>
<given-names>L.G.</given-names>
</name>
<name>
<surname>Zimmers</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia</article-title>
<source/>Am. J. Physiol. Endocrinol. Metab.
          <year>2012</year>
<volume>303</volume>
<fpage>E410</fpage>
<lpage>E421</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00039.2012</pub-id>
<pub-id pub-id-type="pmid">22669242</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-01962">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmers</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Fishel</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Bonetto</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>STAT3 in the systemic inflammation of cancer cachexia</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2016</year>
<volume>54</volume>
<fpage>28</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2016.02.009</pub-id>
<pub-id pub-id-type="pmid">26860754</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-01962">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>SOCS1, SOCS3, and PIAS1 promote myogenic differentiation by inhibiting the leukemia inhibitory factor-induced JAK1/STAT1/STAT3 pathway</article-title>
<source/>Mol. Cell. Biol.
          <year>2009</year>
<volume>29</volume>
<fpage>5084</fpage>
<lpage>5093</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00267-09</pub-id>
<pub-id pub-id-type="pmid">19620279</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-01962">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieskovska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Derman</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Growth impairment in IL-6-overexpressing transgenic mice is associated with induction of SOCS3 mRNA</article-title>
<source/>Growth Horm. IGF Res.
          <year>2003</year>
<volume>13</volume>
<fpage>26</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/S1096-6374(02)00135-1</pub-id>
<pub-id pub-id-type="pmid">12550079</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-01962">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehic</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bakiri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ghannadan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Tschachler</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Fos and jun proteins are specifically expressed during differentiation of human keratinocytes</article-title>
<source/>J. Investig. Dermatol.
          <year>2005</year>
<volume>124</volume>
<fpage>212</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1111/j.0022-202X.2004.23558.x</pub-id>
<pub-id pub-id-type="pmid">15654976</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-01962">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D’Souza</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Koff</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Bruscia</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>6221</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms7221</pub-id>
<pub-id pub-id-type="pmid">25665524</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-01962">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liberati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tetzlaff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement</article-title>
<source/>PLoS Med.
          <year>2009</year>
<volume>6</volume>
<elocation-id>e1000097</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id>
<pub-id pub-id-type="pmid">19621072</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-01962">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulyté</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lorente-Cebrián</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mejhert</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Agustsson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Arner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rydén</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dahlman</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia</article-title>
<source/>Am. J. Physiol. Endocrinol. Metab.
          <year>2014</year>
<volume>306</volume>
<fpage>E267</fpage>
<lpage>E274</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00249.2013</pub-id>
<pub-id pub-id-type="pmid">24326420</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-01962">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moraes</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Vechetti-Júnior</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Freire</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>R.W.A.</given-names>
</name>
<name>
<surname>Villacis</surname>
<given-names>R.A.R.</given-names>
</name>
<name>
<surname>Rogatto</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Dal-Pai-Silva</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>R.F.</given-names>
</name>
</person-group>
<article-title>Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>6998</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-07236-2</pub-id>
<pub-id pub-id-type="pmid">28765595</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-01962">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agarwal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Bartel</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>Predicting effective microRNA target sites in mammalian mRNAs</article-title>
<source/>Elife
          <year>2015</year>
<volume>4</volume>
<fpage>e05005</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.05005</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-01962">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>N.-W.</given-names>
</name>
<name>
<surname>Shrestha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>S.-D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W.-H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.-D.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>H.-C.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>T.-Y.</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>S.-J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database</article-title>
<source/>Nucleic Acids Res.
          <year>2016</year>
<volume>44</volume>
<fpage>D239</fpage>
<lpage>D247</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkv1258</pub-id>
<pub-id pub-id-type="pmid">26590260</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-01962">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dweep</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sticht</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gretz</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>miRWalk–database: Prediction of possible miRNA binding sites by “walking” the genes of three genomes</article-title>
<source/>J. Biomed. Inform.
          <year>2011</year>
<volume>44</volume>
<fpage>839</fpage>
<lpage>847</lpage>
<pub-id pub-id-type="doi">10.1016/j.jbi.2011.05.002</pub-id>
<pub-id pub-id-type="pmid">21605702</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-01962">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Muruganujan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>PANTHER version 11: Expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements</article-title>
<source/>Nucleic Acids Res.
          <year>2017</year>
<volume>45</volume>
<fpage>D183</fpage>
<lpage>D189</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw1138</pub-id>
<pub-id pub-id-type="pmid">27899595</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-01962">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Muruganujan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gaudet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>PANTHER version 7: Improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium</article-title>
<source/>Nucleic Acids Res.
          <year>2010</year>
<volume>38</volume>
<fpage>D204</fpage>
<lpage>D210</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkp1019</pub-id>
<pub-id pub-id-type="pmid">20015972</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-20-01962">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lazareva-Ulitsky</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Loo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kejariwal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vandergriff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rabkin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Muruganujan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Doremieux</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>M.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The PANTHER database of protein families, subfamilies, functions and pathways</article-title>
<source/>Nucleic Acids Res.
          <year>2005</year>
<volume>33</volume>
<fpage>D284</fpage>
<lpage>D288</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gki078</pub-id>
<pub-id pub-id-type="pmid">15608197</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-20-01962">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wyder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Simonovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Doncheva</surname>
<given-names>N.T.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bork</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The STRING database in 2017: Quality-controlled protein–protein association networks, made broadly accessible</article-title>
<source/>Nucleic Acids Res.
          <year>2017</year>
<volume>45</volume>
<fpage>D362</fpage>
<lpage>D368</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw937</pub-id>
<pub-id pub-id-type="pmid">27924014</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-20-01962">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bork</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Huynen</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>STRING: A web-server to retrieve and display the repeatedly occurring neighbourhood of a gene</article-title>
<source/>Nucleic Acids Res.
          <year>2000</year>
<volume>28</volume>
<fpage>3442</fpage>
<lpage>3444</lpage>
<pub-id pub-id-type="doi">10.1093/nar/28.18.3442</pub-id>
<pub-id pub-id-type="pmid">10982861</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-20-01962">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shannon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Markiel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozier</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Baliga</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Ramage</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schwikowski</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ideker</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Cytoscape: A software environment for integrated models of biomolecular interaction networks</article-title>
<source/>Genome Res.
          <year>2003</year>
<volume>13</volume>
<fpage>2498</fpage>
<lpage>2504</lpage>
<pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
<pub-id pub-id-type="pmid">14597658</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-20-01962">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Coffman</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Ainscough</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Spies</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Skidmore</surname>
<given-names>Z.L.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Krysiak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>McMichael</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Eldred</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DGIdb 2.0: Mining clinically relevant drug-gene interactions</article-title>
<source/>Nucleic Acids Res.
          <year>2016</year>
<volume>44</volume>
<fpage>D1036</fpage>
<lpage>D1044</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkv1165</pub-id>
<pub-id pub-id-type="pmid">26531824</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-20-01962">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffith</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Coffman</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Weible</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>McMichael</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Spies</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Koval</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Eldred</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DGIdb: Mining the druggable genome</article-title>
<source/>Nat. Methods
          <year>2013</year>
<volume>10</volume>
<fpage>1209</fpage>
<lpage>1210</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2689</pub-id>
<pub-id pub-id-type="pmid">24122041</pub-id>
</element-citation>
</ref>
</ref-list>
<sec sec-type="display-objects">
<title>Figures, Scheme and Tables</title>
<fig id="ijms-20-01962-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Flow chart of literature search in the meta-analysis.</p>
</caption>
<graphic xlink:href="ijms-20-01962-g001"></graphic>
</fig>
<fig id="ijms-20-01962-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Enrichment pathway analysis of differentially expressed genes in muscle wasting during cancer cachexia. Biological processes identified with up-regulated genes (<italic>p</italic>-value ≤ 0.00253) and down-regulated genes (<italic>p</italic>-value ≤ 0.0364).</p>
</caption>
<graphic xlink:href="ijms-20-01962-g002"></graphic>
</fig>
<fig id="ijms-20-01962-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Protein–protein interaction (PPI) network in muscle wasting in cancer cachexia. Lines highlight PPI, with Stat3, Foxo1, Camk2b, Adipoq, Nr3c1, and Actc1 presenting the highest number of interactions. Colors highlight biological processes or molecular function of the circle network components. The larger the circle, the higher the number of interactions identified. STRING v10.5.1 was used to generate protein interactions, and the resulting network was visualized using Cytoscape v3.4.0.</p>
</caption>
<graphic xlink:href="ijms-20-01962-g003"></graphic>
</fig>
<fig id="ijms-20-01962-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>The miRNA–mRNA target interaction network in muscle wasting in cancer cachexia. (<bold>A</bold>) Interactome between up-regulated genes and the respective potential regulatory microRNAs. The larger the circles, the higher the number of interactions identified. Gray lines highlight the interactions; line thickness reflects the betweenness centrality. (<bold>B</bold>) Interactome between down-regulated genes and the potential regulatory microRNAs. The larger the circles, the higher the number of interactions identified. Gray lines highlight the interactions; line thickness refers to the betweenness centrality. MicroRNA–gene interactions were visualized using Cytoscape v3.4.0.</p>
</caption>
<graphic xlink:href="ijms-20-01962-g004"></graphic>
</fig>
<fig id="ijms-20-01962-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>MicroRNAs and mRNAs identified in muscle wasting in cancer cachexia. (<bold>A</bold>) MicroRNAs predicted in silico as targeting mRNAs retrieved by our meta-analysis (pink circle) were further compared with microRNAs identified as differentially expressed in previous studies of muscle wasting in cancer cachexia, performed by Soares et al. [<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>] (yellow circle) and Narasimhan et al. [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>] (blue circle). (<bold>B</bold>) Venn Diagram comparing the predicted microRNA target for Soares et al. [<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>] (red circle) and Narasimhan et al. [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>] (green circle) with the list of 52 deregulated genes in muscle wasting in cancer cachexia identified in our meta-analysis (purple circle).</p>
</caption>
<graphic xlink:href="ijms-20-01962-g005"></graphic>
</fig>
<fig id="ijms-20-01962-sch001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-01962-sch001_Scheme 1</object-id>
<label>Scheme 1</label>
<caption>
<p>MicroRNA-regulated networks in muscle wasting during cancer cachexia based on meta-analysis data.</p>
</caption>
<graphic xlink:href="ijms-20-01962-sch001"></graphic>
</fig>
<table-wrap id="ijms-20-01962-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-01962-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Description of publicly available studies used in the meta-analysis.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Authors</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Expression Platforms</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Validation Platforms</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Muscle</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cancer Cachexia Study <break></break>(Rodent Model or Cancer Type)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Number of Samples<break></break>(Cachectic/Control)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold><italic>Mus Musculus</italic></bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Tseng et al. 2015</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Illumina HiSeq 2500</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RT</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrocnemius</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Colon-26 adenocarcinoma tumor-bearing mice</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B36-ijms-20-01962">36</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Roberts et al. 2013</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Illumina Genome Analyzer II</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RT, WB</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Quadriceps</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Pancreatic adenocarcinoma-bearing mice</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2/2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B37-ijms-20-01962">37</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Bonetto et al. 2011</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Illumina MouseWG-6 v2.0 expression beadchip</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RT, WB</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Quadriceps</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Colon-26 adenocarcinoma tumor-bearing mice</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4/4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B38-ijms-20-01962">38</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gilabert et al. 2014</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Affymetrix Mouse Gene 1.0 ST Array</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RT</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Biceps femoris</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Pancreatic adenocarcinoma-bearing mice</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B39-ijms-20-01962">39</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Shum et al. 2015</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Affymetrix Mouse Gene 1.0 ST Array</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RT</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrocnemius</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Colon-26 carcinoma tumor-bearing mice</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3/3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B40-ijms-20-01962">40</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Fontes-Oliveira et al. 2014</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Affymetrix RAE230Plus</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Extensor Digitorum Longus</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rats injected with AH-130 Yoshida ascites hepatoma cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7/6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B41-ijms-20-01962">41</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold><italic>Homo Sapiens</italic></bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Martinelli et al. 2016</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Agilent-014850 Whole Human Genome Microarray</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RT, WB</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Rectus abdominis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Pancreatic, colorectal, Hepatic, and renal cancers</td>
<td align="center" colspan="1" rowspan="1" valign="middle">115</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B43-ijms-20-01962">43</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Stephens et al. 2010</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Affymetrix GeneChip Human Genome U133 Plus 2.0 Array</td>
<td align="center" colspan="1" rowspan="1" valign="middle">RT</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Rectus abdominis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal cancer </td>
<td align="center" colspan="1" rowspan="1" valign="middle">18/3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B28-ijms-20-01962">28</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gallagher et al. 2012</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Affymetrix Human Genome U133 Plus 2.0 Array</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Quadriceps</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Upper gastrointestinal cancer</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12/6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B29-ijms-20-01962">29</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>RT: quantitative reverse transcription polymerase chain reaction (RT-qPCR); WB: western blot; Ref: reference.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijms-20-01962-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-01962-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>List of 52 differentially expressed genes of skeletal muscle in cancer cachexia samples.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Official Symbol</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Species</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Function</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Location</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Up-Regulated</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>TIE1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Regulation of angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>EIF3I</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell proliferation, including cell cycling, differentiation and apoptosis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>HGS</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Intracellular signal transduction mediated by cytokines and growth factors</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NUDC</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Neurogenesis and neuronal migration</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PCK1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic pathway that produces glucose</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>TSC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Negatively regulating mTORC1 signaling and playing a role in microtubule-mediated protein transport</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CAMK2B</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Regulation of sarcoplasmic reticulum Ca2+ transport in skeletal muscle</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm; Sarcoplasmic reticulum membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>POLRMT</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Transcription of mitochondrial DNA into RNA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mitochondrion</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>COMP</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Suppressor of apoptosis; interact with extracellular matrix proteins such as the collagens and fibronectin</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted - ECM</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MMP3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Degrade fibronectin, laminin, gelatins, collagens, and cartilage proteoglycans</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted - ECM</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ADIPOQ</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Control of fat metabolism, insulin sensitivity, cell growth, angiogenesis and tissue remodeling</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted - ER</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ANGPTL7</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Anti-angiogenic protein and play a role in extracellular matrix formation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted - ER</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Kcnip4</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Modulates channel expression at the cell membrane</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Pnpla2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Response of the organism to starvation, enhancing hydrolysis of triglycerides and providing free fatty acids to other tissues</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Socs3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Negative regulation of cytokines that signal through the JAK/STAT pathway</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Foxo1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Autophagic cell death induction in response to starvation or oxidative stress</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Stat3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Signal transducer and transcription activator that mediates cellular responses to interleukins and growth factors</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Ufd1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Promote ubiquitination and degradation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>C1s1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Serine protease</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Extracellular exosome; Extracellular space</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Ucp3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Thermogenesis and energy balance</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mitochondrion</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Cebpd</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Immune and inflammatory responses. Transcriptional activator that enhances IL6 transcription</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Junb</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Regulate gene activity following the primary growth factor response</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Fgg</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Guide cell migration during re-epithelialization</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>HP</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Antibacterial activity and plays a role in modulating many aspects of the acute phase response</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Mstn</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Acts specifically as a negative regulator of skeletal muscle growth</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Saa1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Major acute phase protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Serpina3n</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Response to cytokine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>FBXO32</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H, M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Proteasomal degradation of target proteins during skeletal muscle atrophy</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>TRIM63</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">H, M</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulates the proteasomal degradation of muscle proteins and inhibits de novo skeletal muscle protein synthesis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Down-Regulated</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>APCDD1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Negative regulator of the Wnt signaling pathway</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ADCY7</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Membrane-bound, calcium-inhibitable adenylyl cyclase</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>GABARAPL1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Autophagosome maturation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>HINT3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Hydrolyzes phosphoramidate and acyl-adenylate substrates</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NR3C1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Affects inflammatory responses, cellular proliferation, and differentiation in target tissues</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>RCAN1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Central nervous system development</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>HSP90AB1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Maturation, structural maintenance, and proper regulation of specific target proteins involved, for instance in cell cycle control and signal transduction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm, nucleus, cell membrane and secreted</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>HSD11B1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reversibly catalyzes the conversion of cortisol to the inactive metabolite cortisone</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Endoplasmic reticulum membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>BNIP3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mitochondrial protein catabolic process; cell death pathway</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mitochondrion</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>SLC25A37</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mitochondrial iron transporter that specifically mediates iron uptake</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mitochondrion</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PAK1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell adhesion, migration, proliferation, apoptosis, mitosis, and vesicle-mediated transport processes</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm and Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PROX1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">H</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell fate determination, gene transcriptional regulation, and progenitor cell regulation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Cav1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T-cell proliferation and NF-kappa-B activation</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Fap</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Extracellular matrix degradation, tissue remodeling, fibrosis, wound healing, inflammation and tumor growth</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell Membrane</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Actc1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cell motility</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Myh8</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Muscle contraction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Tuba1a</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Constituent of microtubules</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Tuba4a</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Constituent of microtubules</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cytoplasm</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Mef2c</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Controls cardiac morphogenesis and myogenesis, and is also involved in vascular development</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Tfcp2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Binds a variety of cellular promoters, including fibrinogen and alpha-globin promoters</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nucleus</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Lama2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Attachment, migration, and organization of cells by interacting with extracellular matrix components</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted (ECM)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Fst</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">M</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Secreted (ER)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CXCL12</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">H, M</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Immune surveillance, inflammation response, tissue homeostasis, and tumor growth and metastasis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Secreted</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>H: human samples; M: mouse samples; ER: endoplasmic reticulum; ECM: extracellular matrix; SR: sarcoplasmic reticulum.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijms-20-01962-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-01962-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Identification of new relevant microRNA–mRNA interaction in muscle wasting in cancer cachexia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Study</th>
<th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">microRNA/mRNA Interactions</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">microRNA</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA *</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="5" valign="middle">Soares et al. [<xref ref-type="bibr" rid="B35-ijms-20-01962">35</xref>]</td>
<td align="center" colspan="1" rowspan="1" valign="middle">↓ miR-27b</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>↓ Cxcl12</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">↑ miR-140</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>↓ Cxcl12</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">↓ miR-27a</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>↑ Foxo1</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">↓ miR-27a</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>↓ Mef2c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">↓ miR-27b</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>↓ Mef2c</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Narasimhan et al. [<xref ref-type="bibr" rid="B34-ijms-20-01962">34</xref>]</td>
<td align="center" colspan="1" rowspan="1" valign="middle">↑ miR-199a</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>↑ Junb</italic>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">↑ miR-199a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>↓ Cav1</italic>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Up arrow: up-regulated genes; down arrow: down-regulated genes; * mRNAs identified in our meta-analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijms-20-01962-t004" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-01962-t004_Table 4</object-id>
<label>Table 4</label>
<caption>
<p>Potential target agents identified based on protein–protein interaction networks of deregulated genes in cancer cachexia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Symbol</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Name</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Selected Target Agent</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Activity</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Clinical Relevance</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ADIPOQ</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Adiponectin</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Spironolactone, Fenofibrate, Nevirapine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Aldosterone blocker; anti-diabetic and anti-atherosclerotic; antiretroviral therapy</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Type 2 diabetes mellitus; cardiovascular disease;<break></break>HIV infection</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B44-ijms-20-01962">44</xref>,<xref ref-type="bibr" rid="B45-ijms-20-01962">45</xref>,<xref ref-type="bibr" rid="B46-ijms-20-01962">46</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CAMK2B</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Calcium/calmodulin-dependent protein kinase II, beta</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mibefradil, Nifedipine, Nisoldipine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Block T-type calcium channel</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Smooth muscle; cardiac muscle</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B47-ijms-20-01962">47</xref>,<xref ref-type="bibr" rid="B48-ijms-20-01962">48</xref>,<xref ref-type="bibr" rid="B49-ijms-20-01962">49</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>COMP</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Cartilage oligomeric matrix protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tadalafil</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tumor cell growth inhibitory</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Breast cancer</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B50-ijms-20-01962">50</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CXCL12</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Chemokine ligand 12</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Tinzaparin Sodium</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Regulate the proteoglycan core proteins</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Breast cancer</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B51-ijms-20-01962">51</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MSTN</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Myostatin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stamulumab</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Growth/differentiation factor 8 inhibitor</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Myopathies</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B52-ijms-20-01962">52</xref>,<xref ref-type="bibr" rid="B53-ijms-20-01962">53</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</back>
</article>
</pmc-articleset>